This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PCORI Outlines A Patient-Centered Vision For Research And Methodology In JAMA Theme Issue On Comparative Effectiveness Research

WASHINGTON, April 17, 2012 /PRNewswire-USNewswire/ -- Two articles in the April 18 issue of the Journal of the American Medical Association outline the Patient-Centered Outcomes Research Institute's vision for a new, methodologically rigorous focus on patients' needs in comparative effectiveness research (CER).

Such an approach, along with more actively engaging clinicians and other stakeholders in all aspects of the research process, can improve clinical decision-making and ultimately patient outcomes, PCORI Executive Director Joe V. Selby, MD, MPH, Chief Operating Officer Anne C. Beal, MD, MPH, and Lori Frank, PhD, now Director of Engagement Research at PCORI, write in a perspective in the special JAMA CER theme issue.

In a related Special Communication in the same JAMA issue, PCORI's 17-member Methodology Committee discusses the need for rigorous methodological standards and its role in ensuring that PCORI research produces high-integrity information. 

PCORI "was named to emphasize the critical importance of a patient-centered perspective in conducting" CER, Drs. Selby, Beal and Frank write. PCORI's Board of Governors "determined early on that taking this name seriously, placing patients at the center of CER, and actively engaging clinicians and other stakeholders, was an ideal strategy to ensure that PCORI's research agenda stays focused on practical questions, relevant outcomes and study populations and the possibility that treatment effects may differ across patient populations," they add.

The authors also describe PCORI's process for establishing National Priorities for Research and a Research Agenda and what the drafts of those guiding documents, now being revised in response to public input, contain. The draft research agenda provides a preview of the broad-focused research PCORI likely is to support in its first round of primary funding announcements in late May.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs